EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Microvascular, Biochemical, and Clinical Impact of Hyperbaric Oxygen Therapy in Recalcitrant Diabetic Foot Ulcers

Daniela Martins-Mendes iD, Raquel Costa iD, Ilda Rodrigues iD, Óscar Camacho, Pedro Barata Coelho iD, Vítor Paixão-Dias, Carla Luís, Ana Cláudia Pereira iD, Rúben Fernandes iD, Jorge Lima iD, Raquel Soares iD

Cells · 04.08.2025 · 14 (15) · 1196

DOI: 10.3390/cells14151196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 04.08.2025. Verfasst von Daniela Martins-Mendes und 10 weiteren Autor:innen. Beteiligte Einrichtung: RISE-Health, School of Medicine and Biomedical Sciences, Fernando Pessoa University, Fernando Pessoa Teaching and Culture Foundation, Avenida Fernand…. Hauptthemen laut MEDLINE: Diabetic Foot, Hyperbaric Oxygenation, Microvessels. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetic foot ulcers (DFUs) are a serious complication of diabetes and are often difficult to treat. Hyperbaric oxygen therapy (HBOT) has been proposed as an adjunctive treatment to promote healing, but its long-term clinical and biological effects remain insufficiently characterized. This study aimed to evaluate the impact of HBOT on systemic biomarkers, local microvasculature, and clinical outcomes in patients with DFUs.

Methods

In this non-randomized prospective study, 20 patients with ischemic DFUs were followed over a 36-month period. Fourteen received HBOT in addition to standard care, while six received standard care alone. Clinical outcomes—including DFU resolution, recurrence, lower extremity amputation (LEA), and mortality—were assessed alongside systemic inflammatory and angiogenic biomarkers and wound characteristics at baseline and at 3, 6, 12, and 36 months. CD31 immunostaining was performed on available tissue samples.

Results

The two groups were comparable at baseline (mean age 62 ± 12 years; diabetes duration 18 ± 9 years). At 3 months, the HBOT group showed significant reductions in erythrocyte sedimentation rate and DFU size (p < 0.05), with downward trends observed in C-reactive protein (CRP), vascular endothelial growth factor (VEGF), and placental growth factor (PlGF), and an increase in stromal-derived factor-1 alpha (SDF1-α). No significant changes were observed in the control group. CD31+ microvessel density appeared to increase in HBOT-treated DFU tissue after one month, although the sample size was limited. Patients receiving HBOT had lower rates of LEA and mortality, improved wound healing, and sustained outcomes over three years. DFU recurrence rates were similar between groups.

Conclusions

HBOT was associated with improved wound healing and favorable biomarker profiles in patients with treatment-resistant ischemic DFUs. While these findings are encouraging, the small sample size and non-randomized design limit their generalizability, highlighting the need for larger, controlled studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic FootHyperbaric OxygenationMicrovesselsHumansMiddle AgedMaleFemaleWound HealingAgedBiomarkersProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

angiogenesisdiabetesdiabetic footfoot ulcerhyperbaric oxygen therapymicrovessel density

Substanzen

Biomarkers

Autor:innen und Institutionen

  • RISE-Health, School of Medicine and Biomedical Sciences, Fernando Pessoa University, Fernando Pessoa Teaching and Culture Foundation, Avenida Fernando Pessoa 150, 4420-096 Gondomar, Portugal.
  • CECLIN-Centre of Clinical Studies, Hospital Fernando Pessoa, Avenida Fernando Pessoa 150 São Cosme, 4420-096 Gondomar, Portugal.
  • Fernando Pessoa-Biomedical Health Sciences (FPBHS), FP-I3ID-Instituto de Investigação, Inovação e Desenvolvimento, University Fernando Pessoa, Praça de 9 de Abril 349, 4249-004 Porto, Portugal.
  • Bomedicine Department, Faculty of Medicine, University of Porto, Alameda Prof Hernâni Monteiro, 4200-319 Porto, Portugal.
  • Centro de Biotecnologia e Química Fina Laboratório Associado, Escola superior de Biotecnologia, Universidade Católica Portuguesa, R. de Diogo Botelho 1327, 4169-005 Porto, Portugal.
  • i3S-Instituto de Investigação e Inovação em Saúde, University of Porto, 4200-135 Porto, Portugal.

ORCID-Profile: Daniela Martins-Mendes, Raquel Costa, Ilda Rodrigues, Pedro Barata Coelho, Ana Cláudia Pereira, Rúben Fernandes, Jorge Lima, Raquel Soares

Zitieren

APA

Martins-Mendes, D., Costa, R., Rodrigues, I., Camacho, Ó., Coelho, P. B., Paixão-Dias, V., Luís, C., Pereira, A. C., Fernandes, R., Lima, J., & Soares, R. (2025). Microvascular, Biochemical, and Clinical Impact of Hyperbaric Oxygen Therapy in Recalcitrant Diabetic Foot Ulcers. Cells, 14(15), 1196. https://doi.org/10.3390/cells14151196

Vancouver

Martins-Mendes D, Costa R, Rodrigues I, Camacho Ó, Coelho PB, Paixão-Dias V, et al. Microvascular, Biochemical, and Clinical Impact of Hyperbaric Oxygen Therapy in Recalcitrant Diabetic Foot Ulcers. Cells. 2025;14(15):1196. doi:10.3390/cells14151196

BibTeX
@article{MartinsMendes2025,
  author = {Martins-Mendes, Daniela and Costa, Raquel and Rodrigues, Ilda and Camacho, Óscar and Coelho, Pedro Barata and Paixão-Dias, Vítor and Luís, Carla and Pereira, Ana Cláudia and Fernandes, Rúben and Lima, Jorge and Soares, Raquel},
  title = {Microvascular, Biochemical, and Clinical Impact of Hyperbaric Oxygen Therapy in Recalcitrant Diabetic Foot Ulcers},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {15},
  pages = {1196},
  doi = {10.3390/cells14151196}
}
Kostenlos starten →